Lung cancer contributes to a poor prognosis in patients with idiopathic pulmonary fibrosis (IPF), a new study indicates. The finding suggests that healthcare professionals should monitor the development and progression of cancer in patients with IPF, given its negative impact on prognosis. The study, “Prognostic impact of malignant…
Lung Cancer Contributes to Poor Prognosis in IPF, Study Suggests
FibroGen’s experimental antifibrotic therapy pamrevlumab may be more effective than Esbriet (pirfenidone) and Ofev (nintedanib) at slowing disease progression in people with idiopathic pulmonary fibrosis (IPF), according to a review study. Combined data from eight clinical trials showed that all three therapies significantly…
Earlier this month, I wrote a column about mental health and therapy options available during the pandemic. Hopefully, I made a strong case for giving therapy a try if you have been hesitant. I will always encourage people to try it out, but I…
The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of free virtual workshops in December, with the aim of empowering leaders to start non-profit organizations and research programs to help people with rare diseases. “The RareLaunch program is…
A photo of a bespectacled young boy, his red baseball cap slightly askew as he enjoys time outside, will be featured on the front cover of an upcoming calendar in the “Same But Different” contest to raise awareness about rare disorders. “A Lovely Day Out in Kew Gardens,”…
Many people around the world complain about the cold, dark winter months. This is even true for Canadians who “should” be used to the frigid temperatures our country experiences every year. I know more people dislike the cold than the heat, but cold weather doesn’t pose health risks to…
The combination of CB5138-2 — an experimental peptide, or small protein — and Ofev (nintedanib) reduced symptoms of idiopathic pulmonary fibrosis (IPF) better than Ofev alone in a preclinical study. Together, CB5138-2 (developed by CohBar) and Ofev (an approved IPF therapy marketed by Boehringer Ingelheim)…
ARDS-003, Tetra Bio-Pharma’s investigational medication for the treatment of hyperinflammatory lung injury, showed an anti-inflammatory effect in pre-clinical studies using a mouse model of pulmonary fibrosis (PF) and could be considered for the treatment of COVID-19, the company announced. Apart from reducing inflammation, the therapy also lessened…
A decrease in health-related quality of life (HRQoL) in people with idiopathic pulmonary fibrosis (IPF) is mainly associated with respiratory and emotional symptoms, a study shows. Routine assessment of these symptoms is important, as they may be related to other ones affecting HRQoL, researchers say. The study, “…
A Phase 2 study of Haduvio (nalbuphine extended release tablets) to treat chronic cough in people with idiopathic pulmonary fibrosis (IPF) is again enrolling eligible patients, Trevi Therapeutics, the therapy’s developer, announced. The U.K. trial was placed on hold due to the COVID-19 pandemic, as IPF patients…
